AJP - Regu Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Regul Integr Comp Physiol 295: R1020-R1030, 2008. First published August 6, 2008; doi:10.1152/ajpregu.90389.2008
0363-6119/08 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
295/4/R1020    most recent
90389.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Williamson, M.
Right arrow Articles by Viau, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Williamson, M.
Right arrow Articles by Viau, V.

CALL FOR PAPERS
Neural Integration of Peripheral Signals Implicated in the Control of Energy Homeostasis and Metabolism

Selective contributions of the medial preoptic nucleus to testosterone-dependant regulation of the paraventricular nucleus of the hypothalamus and the HPA axis

Martin Williamson and Victor Viau

Neuroscience Program, Department of Cellular and Physiological Sciences, University of British Columbia, Vancouver, British Columbia, Canada

Submitted 26 April 2008 ; accepted in final form 31 July 2008


    ABSTRACT
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Previous data have consistently demonstrated an inhibitory effect of androgens on stress-induced hypothalamic-pituitary-adrenal (HPA) responses. Several brain regions may influence androgen-mediated inhibition of the HPA axis, including the medial preoptic area. To test the role of the medial preoptic nucleus (MPN) specifically, we examined in high- and low-testosterone-replaced gonadectomized rats bearing discrete bilateral lesions of the MPN basal and stress-induced indexes of HPA function, and the relative levels of corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP) mRNA in the amygdala. High testosterone replacement decreased plasma adrenocorticotropin hormone (ACTH) and paraventricular nucleus (PVN) Fos responses to restraint exposure in sham- but not in MPN-lesioned animals. AVP-, but not CRH-immunoreactivity staining in the external zone of the median eminence was increased by testosterone in sham animals, and MPN lesions blocked this increment in AVP. A similar interaction between MPN lesions and testosterone occurred on AVP mRNA levels in the medial nucleus of the amygdala. These findings support an involvement of MPN projections in mediating the AVP response to testosterone in both the medial parvocellular PVN and medial amygdala. We conclude that the MPN forms part of an integral circuit that mediates the central effects of gonadal status on neuroendocrine and central stress responses.

corticotropin releasing hormone; arginine vasopressin; Fos; adrenocorticotropin; corticosterone; medial amygdala; hypothalamic-pituitary-adrenal axis


THE VAST DISTRIBUTION OF DIFFERENT types of sex steroid hormone receptors within the central nervous system place this class of hormones well beyond the realm of reproductive function (56). Indeed, testosterone and estrogen exert reliable inhibitory and stimulatory effects, respectively, on activity of the hypothalamic-pituitary-adrenal (HPA) axis, a neuroendocrine system essential for survival (55). Moreover, individual and gender-based differences in normal and abnormal HPA function can be attributed to variations in sex steroid hormone release (46, 51).

Threats to homeostasis activate the HPA axis by triggering the sequential release of a chain of hormones. This is initiated by the recruitment of neurosecretory neurons in the paraventricular nucleus (PVN) of the hypothalamus that secrete peptide stores from the median eminence, primarily corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP) (44). CRH and AVP synergize on the release of adrenocorticotropin hormone (ACTH) from the anterior pituitary that, in turn, stimulates the release of glucocorticoids from the adrenal gland, cortisol in humans, and corticosterone in the rat (1, 3). A fine balance between glucocorticoid negative feedback inhibition and stress-induced drive to the HPA axis ultimately determines the magnitude of the ACTH response to stress (10, 54). Testosterone can operate on all of these elements by exerting inhibitory actions on the cellular and transcriptional activation of PVN motor neurons, ACTH secretagogue synthesis and release, as well as by enhancing glucocorticoid negative feedback efficacy (47, 49).

There are multiple sites and pathways mediating the central actions of androgens on the HPA axis. Various metabolites of testosterone, including 5{alpha}-dihydrotestosterone and its 3β-diol metabolite, are capable of acting locally to inhibit stress-induced levels of PVN Fos mRNA and plasma ACTH and corticosterone (26). Our connectional studies predict that androgens can also act within a very large assortment of brain regions relaying sensory and limbic information to the PVN region. The medial preoptic nucleus (MPN) stands out in this regard, as we found that it contains the highest concentration of androgen receptor (AR) positive efferents to the PVN (56). In line with this connectional data, testosterone implants in the vicinity of the MPN reduce the plasma ACTH and corticosterone responses to restraint (50). Moreover, high testosterone replacement levels in the periphery that normally suppress the magnitude of the HPA stress response fail to do so in rats bearing large electrolytic lesions of the medial preoptic area (50).

At this point, several uncertainties remain. First, while these electrolytic lesions in the medial preoptic area encompassed the MPN, they were also large enough to have damaged several neighboring subcortical relays to the PVN region. This would include the anterior hypothalamic area; the ventral noradrenergic ascending bundle, which travels through the lateral hypothalamic and lateral preoptic areas; and the posterior medial region of the bed nucleus of the stria terminalis (BST), which markedly inhibits HPA responses to acute stress (8, 9). Second, while systemic changes in testosterone can operate on CRH and AVP expression and stress-induced levels of Fos within PVN motor neurons (27, 48), the extent to which a functioning MPN is necessary for these synthetic and cellular stress responses to occur remains to be seen.

In the present study, we superimposed two levels of testosterone replacement in the periphery in animals receiving sham or small-volume, bilateral injections of ibotenic acid in the MPN. This allowed us to assess how testosterone acts and interacts with the MPN on ACTH secretagogue synthesis, HPA output, and intervening levels of Fos activation within different compartments of the PVN. Of note, the MPN receives and sends input to the medial nucleus of the amygdala (7, 39), one of many limbic regions expressing ARs (56) and regulating the HPA axis (11). Testosterone stimulates AVP mRNA and peptide in the medial amygdala (12), and several lines of evidence continue to relate the inhibitory influence of the gonadal axis on HPA function in males to testosterone-dependent increases in extrahypothalamic AVP (17, reviewed in Ref. 55). Based on the potential for the MPN to influence the HPA axis to and through AVP neurons in the medial amygdala, we gauged whether the AVP response to testosterone within this structure also depends on the integrity of the MPN. Our findings indicate that the MPN is integral for testosterone to act on the PVN, as well as its extended circuitries.


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Animals. Eighty-eight adult male Sprague-Dawley rats (Charles River, St. Constant, Canada) were used, weighing 250 g on arrival (56 days old) and 375 g when sampled (~75 days old). Animals were pair housed under controlled temperature (23 ± 2°C) and lighting conditions (12:12-h light-dark cycle, lights on at 0600), with food (Labdiet; Rat diet 5012) and water available ad libitum. All experimental protocols were approved by the University of British Columbia Animal Care Committee.

Treatment. To explore how testosterone interacts with the MPN, body weight-matched animals were gonadectomized (GDX), randomly assigned to one of four replacement-MPN treatment combinations [1) low testosterone-sham, 2) low testosterone-lesion, 3) high testosterone-sham, and 4) high testosterone-lesion], and sampled under basal and/or restraint stress conditions.

Testes were removed via a scrotal incision under ketamine-xylazine-acepromazine anesthesia (25, 5, and 1 mg/ml, respectively; 1 ml/kg sc). Each testis was delivered separately through the scrotal incision and removed by severing the vas deferens and spermatic artery, which was ligated to maintain hemostasis. Gonadectomy was completed by closing the scrotal incision with 4–0 nonabsorbable suture. Testosterone replacement was performed at the same time, using two subcutaneous Silastic implants (each 35 mm in length, 0.062 mm inner diameter, 1.25 mm outer diameter; Dow Corning, Midland, MI) that were packed with crystalline testosterone (Sigma Aldrich, Oakville, Canada) to a length of 10 or 60 mm for low and high testosterone replacement, respectively (22). As shown in RESULTS, these implants provide plasma testosterone concentrations in the physiological range observed in adult male rats (48, 50).

MPN lesions. Comparing the effects of MPN lesions in gonadal-intact and GDX rats with or without testosterone replacement was initially considered. However, this is not the most informative approach for establishing that the MPN is an obligate target for the central actions of testosterone on the HPA axis to occur. As our previous connectional experiments suggest (56), there are likely several candidate structures in the brain supplying androgen-sensitive input to the PVN region, in addition to the MPN. Importantly, gonadotropin-releasing hormone neurons are diffusely distributed throughout a continuum of the medial basal forebrain, including within the region of the MPN (20, 37). Because lesions in the vicinity of the MPN can decrease circulating testosterone levels in animals with testes (23), this approach would not allow us to discern a role for the MPN independent from changes in testosterone release. GDX rats show increases in HPA activity similar to those bearing MPN lesions (48). Thus data gleaned from these animals would also lack the specificity for attributing the central effects of testosterone to the MPN. In light of these uncertainties, in the present study, we superimposed two levels of testosterone replacement in GDX animals bearing MPN lesions, both to control for testosterone and to specifically address whether the MPN is required for the HPA axis to register differences in testosterone in circulation.

After gonadectomy and testosterone replacement surgeries (3 days), rats were anesthetized by injection of pentobarbital sodium (50 mg/kg ip) and were placed in a Kopf stereotaxic apparatus. To produce discrete, axon-sparing lesions (see Ref. 23), rats received bilateral volume injections of ibotenic acid (100 nl, 5 µg/µl in 0.1 M PBS, pH 7.2; Sigma Chemicals, Oakville, Canada) or PBS (sham lesion; 0.1 M, pH 7.2) in each MPN sequentially (0.15 mm rostral to bregma, 0.4 mm lateral to the midsagittal sinus, 7.75 mm below the pial surface; bite bar set at 3 mm below the ear bars) using a Hamilton microsyringe (32 gauge blunt needle; Hamilton, Reno, NV). The syringe was lowered and kept in position for 5 min before injection, which was then delivered at a rate of 10 nl/min over a 10-min period. To reduce diffusion along the pipette track, the syringe was left in place for an additional 15 min before removal. One series of sections through the region of the MPN was counterstained with thionin to examine needle track location and neuron loss. Two additional adjacent series were processed to determine patterns of gliosis and AR staining. As described in greater detail in RESULTS, tissue and blood samples from animals bearing improper or ineffective MPN lesions were removed from the analysis.

Tissue and blood collection. Animals were weighed daily and allowed to recover for 14 days before restraint exposure, which involved placing rats in flat-bottom Plexiglas restrainers (8.5 x 21.5 cm; Kent Scientific, Litchfield, CT) for 30 min and then returning them to their home cage for an additional 30-min period. Blood samples obtained from the tail vein were collected in ice-chilled aprotinin- and EDTA-treated tubes (3.75 mg EDTA/100 µl of blood), centrifuged at 3,000 g for 20 min, and stored at –20°C until assayed. Blood samples were obtained immediately following removal from the home cage (0 min), at the end of restraint (30 min), and 30 min following the termination of restraint (60 min). All testing was performed during the light phase of the cycle, beginning at 0800.

Rats were anesthetized for perfusion after a tail blood sample was taken, either following home cage removal or 60 min following the onset of restraint. Based on our previous time course studies, the 30-min poststress interval is optimal for detecting, within individual animals, both the relative differences in stress-induced indexes of HPA function and intervening levels of Fos in PVN attributable to differences in gonadal status (48). As verified by corneal and pedal pinch reflexes, deep anesthesia was reliably achieved within 1–2 min of chloral hydrate administration (40% wt/vol in dH20; 1 ml/100 g body wt ip). Rats were perfused via the ascending aorta with 0.9% saline, followed by 4% paraformaldehyde (pH 9.5), both at 4°C. Saline and fixative were delivered over 5 and 20 min, respectively, at a flow rate of 20 ml/min. Brains were postfixed for 4 h and cryoprotected overnight with 15% sucrose in 0.1 M potassium PBS (KPBS; pH 7.3) before slicing. Five 1-in-5 series of frozen 30-µm-thick coronal sections through the length of the brain were collected and stored in antifreeze (30% ethylene glycol and 20% glycerol in sterile diethyl pyrocarbonate-treated water) at –20°C until processing. Adjacent series of tissues from each animal were used for in situ hybridization- and immunohistochemical analyses. In all cases, an additional series was counterstained with thionin and alternately compared with dark- and bright-field illuminations for morphological and anatomical reference.

Plasma hormones. Plasma testosterone (25 µl), corticosterone (5 µl, diluted 1:200 as per kit instructions), and ACTH (50 µl) concentrations were measured using commercial RIA kits (MP Biomedical, Solon, OH). For corticosterone, the plasma samples were diluted 1:100 and 1:200 for prestress and poststress time intervals, respectively, to render hormone detection within the linear part of the standard curve. The intra- and interassay coefficients of variation for all of the assays typically ranged from 3 to 6 and 10 to 12%, respectively, and 125I-labeled ligands were used as tracer in all cases.

The testosterone antibody cross-reacts 100% with testosterone and slightly with 5{alpha}-dihydrotestosterone (3.40%), 5{alpha}-androstane-3β, 17β-diol (2.2%), and 11-oxotestosterone (2%). The standard curve ED50 for the testosterone RIA was 1.2 ng/ml, with a detection limit of 0.1 ng/ml. The corticosterone antibody cross-reacts 100% with corticosterone and slightly with desoxycorticosterone (0.34%), testosterone, and cortisol (0.10%) but does not react with the progestins or estrogens (<0.01%). The standard curve ED50 for the corticosterone RIA was 17 µg/dl, with a detection limit of 0.625 µg/dl. The ACTH antibody cross-reacts 100% with ACTH1–39 and ACTH1–24, but not with β-endorphin, {alpha}- and β-melanocyte-stimulating hormone, and {alpha}- and β-lipotropin (all <0.8%). The standard curve ED50 for the ACTH RIA was 82 pg/ml, with a detection limit of 20 pg/ml.

Immunohistochemistry. Lesion placement in the MPN was determined by analyzing patterns of Nissl staining, glial cell infiltration (glial fibrillary acidic protein, GFAP), and AR staining within adjacent tissue series. Glial cell infiltration was identified using a primary antiserum purified from bovine GFAP (AB5804, lot no. 0506002852; Millipore, Billerica, MA; 1:2,000). AR immunoreactive neurons were localized using a primary antiserum (0.025 µg/ml; 1:8,000) raised against the NH2-terminal amino acids 2–20 of the AR (sc-816, lot no. E1004; Santa Cruz Biotechnology, Santa Cruz, CA). Restraint-responsive neurons in the PVN were localized using Fos-immunoreactivity (ir) as a marker of cellular activation using a primary antiserum (1:45,000) raised against amino acids 4–17 of the human Fos protein (Ab-5, lot no. 4191–1-1; Oncogene Research Products, Boston, MA).

Free-floating sections were first rinsed in KPBS buffer to remove cryoprotectant and then pretreated with 0.3% hydrogen peroxide for 10 min to quench endogenous peroxidase activity. This was followed by four rinses in KPBS and then in sodium borohydride (1% wt/vol in KPBS) for 5 min to reduce free aldehydes. Sections were then incubated for 48 h at 4°C in a KPBS-Triton (0.3% Triton X; Sigma-Aldrich, Oakville, Ontario) solution containing 2% normal goat serum and the primary antiserum to detect AR or Fos, as described above. AR and Fos primary antisera were detected using a conventional nickel-intensified, avidin-biotin-immunoperoxidase (Vectastain Elite ABC kit; Vector laboratories, Burlington, CA) procedure (24). GFAP was detected by using a nonnickel variant of the procedure, as previously described (25). Control experiments, in which the primary antisera to AR or Fos were preadsorbed for 24 h at 4°C with excess synthetic peptide immunogen, corresponding to NH2-terminal amino acids 2–21 of the rat AR (0.25 µM, sc-816-P, EVQLGLGRVYPRPPSKTYRG; Santa Cruz Biotechnology) or to amino acids 4–17 of the human c-fos (50 µM, PP10, SGFNADYEASSSRC; Oncogene Research Products), failed to yield any evidence of specific AR or Fos staining. Additional control experiments involving the omission of either primary or secondary antibody yielded no specific labeling.

Discrete localization of Fos-ir profiles to the medial dorsal parvocellular (mpd; neurosecretory, anterior pituitary-regulating) and to the dorsal and medial ventral parvocellular (dp and mpv, respectively; nonneurosecretory, autonomic regulating) populations of the PVN was assisted by redirected sampling of an adjacent series of thionin-stained sections. Total cell number estimates of Fos-positive cells were generated by counting bilaterally the number of Fos-positive cells through each region of interest, averaged by dividing the total number of cell counts by slice number, corrected for double counting errors (19), and multiplying this product by a factor of five to account for slice frequency (1 in 5 sections).

Characterization of CRH and AVP staining in the median eminence was performed using a dual immunohistochemical labeling technique, including a rabbit polyclonal antibody against CRH (T-4037, lot no. 970177-1; 1:2,000; Bachem, Torrance, CA) and a guinea pig antibody against AVP (T-5048, lot no. 061305; 1:25,000; Bachem). Free-floating tissue was prepared as described above, with slight modifications of these procedures to optimize double labeling for CRH- and AVP-ir, including 1) the elimination of hydrogen peroxide pretreatment, 2) using BSA as a blocking agent, and 3) incubating tissue sections in primary antisera for 24 h at 4°C. Primary antisera against CRH and AVP were detected using conjugated anti-rabbit IgG (Alexa 594; 1:500; Invitrogen) and anti-guinea pig IgG (1:500; Alexa 488, Invitrogen) fluorescent secondary antibodies, respectively. Concurrent immunofluorescence detection of CRH- and AVP-ir in the median eminence was achieved under appropriate fluorescence wavelength conditions, using a Texas red filter (Leica TX2 no. 513843) to detect Alexa 594 under 480 ± 40 nm excitation and 527 ± 30 emission and a fluorescein isothiocyanate filter (Leica L5 no. 513840) to detect Alexa 488 under 560 ± 40 nm excitation and 645 ± 75 emission wavelengths. Control experiments in which the primary antisera to CRH and AVP were preadsorbed with excess levels of their respective immunogens failed to yield any evidence of specific staining. Furthermore, experiments involving the cross adsorption of excess amounts of CRH and AVP, in addition to the omission of either primary or secondary antibody, provided no evidence of cross-reactivity of the CRH primary to detect AVP nor the AVP primary antibody to detect CRH.

A Leica 40X HCL PL Fluotar objective was used to quantify CRH- and AVP-ir localized to the external lamina of the median eminence, the anterior pituitary-directed part of the structure. Optical images from 10 regularly spaced (150 µm) sections through the median eminence were acquired and binarized using constant acquisition and threshold parameters. Binarized images were further skeletonized, and the total average density of pixels was recorded as a measure of staining intensity. Parvocellular PVN neurosecretory neurons are acknowledged as the principal source of CRH-ir terminals in the external zone of the median eminence (24, 60). Determination of AVP staining within terminals specific to this PVN cell population was achieved by redirected sampling of CRH and AVP staining and by quantifying only those AVP profiles superimposed by CRH-positive nerve terminals.

Hybridization histochemistry. A hybridization approach was used under basal conditions to identify how testosterone acts independently or interacts with the MPN on the relative levels of CRH and AVP mRNA in the central and medial nucleus of the amygdala, respectively. CRH and AVP mRNA hybridization histochemistry were carried out using [33P]UTP-labeled (GE Healthcare Bio-Sciences, Baie d'Urfe, Canada) antisense cRNA probes transcribed from a full-length (1.2 kb) cDNA encoding the rat CRH gene and a 230-bp fragment from the 3'-end of exon C encoding the rat vasopressin gene. Techniques for riboprobe synthesis, hybridization, and the patterns of hybridization for these probes in the amygdala are described in greater detail elsewhere (41, 53). Based on the strength of the hybridization signal on X-ray film (β-max; Amersham), the hybridized slides were then coated with Kodak NTB2 liquid autoradiographic emulsion and exposed at 4°C in the dark with desiccant. Exposure time to emulsion was optimized to ensure that mRNA levels detected were within the linear range of the assay and could be quantified by making relative comparisons in optical density (OD) levels (12 days for CRH mRNA in the central amygdala; 24 days for AVP mRNA in the medial amygdala). Using a standard reference frame, average OD values were determined bilaterally on six and four regularly spaced (150 µm) intervals through the central and medial amygdala, respectively, and corrected by background subtraction. Hybridized tissue series were aligned using white matter morphology illuminated under darkfield conditions and the cytoarchitectonic features provided by an adjacent series of Nissl-stained material.

Parceling of the rat brain followed the mapping of Fos-ir in the PVN, and CRH and AVP mRNA in the amygdala, as defined by the morphological features provided by thionin staining of adjacent series of tissue, based on the terminology of Swanson (42), and of Swanson and Kuypers (43), Swanson and Simmons (45), and Viau and Sawchenko (52) to describe the PVN, of Dong and Swanson (14) to describe the BST, and of Canteras et al. (7) and Dong and colleagues (13) to describe the central and medial amygdala. Features and terminology to describe the MPN were based on Simerly et al. (38–40). Light- and dark-level images were captured using a Retiga 1300 CCD digital camera (Q-imaging, Burnaby, BC), analyzed using Macintosh OS X-driven, Open Lab Image Improvision version 3.0.9 (Quorum Technologies, Guelph, ON) and ImageJ version 1.38 software (NIH, Bethesda, MD), and exported to Adobe Photoshop (version 10.0; San Jose, CA), where standard methods were used to adjust contrast and brightness, and final assembly at a resolution of 300–600 dpi.

Statistics. Data are expressed as means ± SE and were analyzed by using a two- and three-way ANOVA to detect testosterone replacement and MPN lesion effects on Fos under stress conditions, as well as CRH- and AVP-based data under basal conditions. ACTH and corticosterone were analyzed by ANOVA using one repeated measure (time of sample). Significant ANOVAs were followed using Newman-Keul's post hoc test. Immuno- and in situ hybridization-histochemical and hormone comparisons were made observer-blind by assigning coded designations to the data sets in advance.


    RESULTS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
MPN lesions. Our pilot studies indicated that bilateral lesions that were centered within, but biased toward, the caudal part of the nucleus were most reliable in terms of inducing elevated plasma ACTH responses to stress. Pilot studies employing a unilateral lesion approach in gonadal intact animals demonstrated a complete loss of AR staining in the ipsilateral, but not in the contralateral, MPN. Furthermore, beyond sparing the amount of damage to fibers of passage (11), the volume and concentration of ibotenic acid used were effective in producing lesions that were histologically distinct and consistently uniform in the animals chosen for analysis.

The extent of the excitotoxin lesions was reliably demarcated by examining local patterns of GFAP induction and loss of AR staining (Figs. 1 and 2). The caudal part of the MPN is conspicuously composed of magnocellular neurons (38–40) and shows a high density of AR staining that almost completely mirrors its contours. Compared with shams, a lesion was deemed effective in animals showing a loss of AR staining and magnocellular material, as well as glial infiltration that was centered within the caudal part of the MPN. In general, cellular damage was restricted to the MPN; however, slight damage was occasionally observed within cells occupying the neighboring medial preoptic area and ventral portions of the posterior division of the BST, including the interfascicular nucleus (see Fig. 1). Although we cannot rule out completely the possible influence of these regions, the interfascicular nucleus has little direct input to the PVN (14). Furthermore, the principal nucleus, clearly spared in all of the animals examined, appears to be the major subnucleus of the posterior BST responsible for regulating the HPA axis (8, 9).


Figure 1
View larger version (111K):
[in this window]
[in a new window]

 
Fig. 1. Histological identification of ibotenic lesions in the medial preoptic nucleus (MPN). Representative adjacent bright- and darkfield photomicrographs to show androgen receptor (A and B) and glial fibrillary acidic protein (C and D) staining through a comparable level of the MPN in animals bearing sham (A and C) and MPN (B and D) lesions. Compared with shams (A and C), ibotenic lesions (B–D) caused a marked reduction in androgen receptors and glial infiltration in the area occupied by the caudal part of the nucleus. Structures labeled for reference as follows: fx, fornix; GPe, globus pallidus, external segment; pBST, bed nucleus of the stria terminalis, posterior division. Scale bar = 500 µm (applies to all).

 

Figure 2
View larger version (13K):
[in this window]
[in a new window]

 
Fig. 2. Schematic representations to describe cell damage through the rostrocaudal extent (A–D) of the MPN, assisted by cell morphology, androgen receptor, and glial infiltration patterns within adjacent tissue series. The red line describes the nuclear boundaries of the MPN. The areas colored in light and dark blue describe the full extent and common regions of damage, respectively, in animals showing proper ibotenic lesions. AP values describe the relative distance from bregma (mm) for each slice interval [atlas plates based on Swanson (42)].

 
Rats showing unilateral or nonuniform bilateral lesions were removed from subsequent analysis. Furthermore, animals bearing lesions that were focused beyond the intended caudal part of the MPN or showing damage that extended well into the lateral preoptic and anterior hypothalamic areas were also excluded. Peptide-ir, mRNA, and stress hormone data were analyzed in only those animals showing proper lesions in the MPN, as independently verified by an observer who was blind to the experimental design. Based on the exclusion criteria described, a final "n" of six per group was achieved for each of the four testosterone replacement-MPN treatment combinations.

Body weights. There was a main effect of lesion [F(1,44) = 4.3; P < 0.05] and a significant lesion x time interaction [F(2,88) = 15.0; P < 0.01] on body weight gain, but no effect of testosterone replacement. Differences in body weight gain during the first postsurgical week contributed to this interaction. During this interval, there was a significant effect of lesion [F(1,44) = 19.6; P < 0.01], as shams showed significantly higher body weight gains (P < 0.05) than did MPN-lesion animals, 4.6 ± 0.5 and 0.8 ± 0.6 g/day, respectively. However, there was no main effect of testosterone (P = 0.83) and no lesion x testosterone interaction (P = 0.98) on body weight gain during the first postsurgical week. By the second postsurgical week immediately before stress testing, body weight gains were comparable between sham and MPN-lesion animals, 6.1 ± 0.4 and 6.8 ± 0.5 g/day, respectively. Analysis of absolute body weights on the final day of testing indicated a main effect of testosterone replacement [F(1,44) = 5.5; P < 0.05] but no significant effect of lesion or a significant testosterone x lesion interaction. Low-testosterone-replaced animals showed higher body weights than their high-testosterone-replaced counterparts: 370.5 ± 4.4 and 355.5 ± 5.2 g, respectively. Taken together, these findings indicate that the destruction of the MPN did not contribute to changes in growth by the time of testing, whereas testosterone contributed to differences in body weight.

Testosterone replacement and HPA hormones. In GDX, low- and high-testosterone-replaced rats, plasma testosterone concentrations were 0.48 ± 0.07 and 2.58 ± 0.08 ng/ml, respectively, validating the reliability of our testosterone replacement regimen.

Analysis of plasma ACTH revealed significant main effects of lesion [F(1,20) = 9.3; P < 0.01], testosterone [F(1,20) = 27; P < 0.01], and restraint [F(2,40) = 216; P < 0.01]. Lesion x testosterone [F(1,20) = 5.7; P < 0.05] and lesion x testosterone x restraint [F(2,20) = 6.5; P < 0.05] interactions were both significant. Post hoc analysis revealed no differences in prestress levels of ACTH. Compared with shams, rats with MPN lesions showed higher levels of ACTH under stress conditions, at both 30 and 60 min of restraint exposure (Fig. 3A).


Figure 3
View larger version (38K):
[in this window]
[in a new window]

 
Fig. 3. Mean ± SE plasma adrenocorticotropic hormone (ACTH, A) and corticosterone (B) concentrations before (0 min) and 30 and 60 min following the onset of a single 30-min episode of restraint in gonadectomized (GDX), low- and high-testosterone-replaced rats bearing sham and ibotenic (IBO) lesions in the MPN (n = 6/group). *P < 0.05 vs. low-testosterone sham and both low- and high-testosterone-replaced, MPN lesion animals (A). *P < 0.05 indicates a main effect of MPN lesions on corticosterone, regardless of testosterone replacement (B).

 
Analysis of plasma corticosterone revealed significant main effects of lesion [F(1,20) = 9.3; P < 0.01] and restraint [F(2,40) = 233; P < 0.01]. There was no main effect of testosterone and no significant lesion x testosterone interaction. Thus, in contrast to the ACTH response within shams, there was no apparent inhibitory effect of testosterone on corticosterone levels at 30 and 60 min of restraint. However, both lesion x restraint [F(2,40) = 6.2; P < 0.01] and lesion x testosterone x restraint [F(2,40) = 3.6; P < 0.05] interactions were significant, signifying a capacity for the MPN lesions to influence corticosterone. Indeed, post hoc analysis confirmed a stimulatory effect of MPN lesions on plasma corticosterone levels immediately before and during restraint, regardless of testosterone replacement (Fig. 3B).

Parvicellular PVN Fos-ir. Quantitative assessment of the number of Fos-positive cells within regions of the parvicellular division of the PVN (Figs. 4 and 5) revealed significant main effects of lesion [F(1,40) = 6.2; P < 0.05], testosterone replacement [F(1,40) = 10.7; P < 0.01], and restraint [F(1,40) = 1,763; P < 0.01], as well as a significant lesion x testosterone x restraint x region [F(2,80) = 9.4; P < 0.01] interaction. There were no main effects of lesion or testosterone under basal conditions, neither between or within the medial parvocellular regions analyzed. As a function of stress, there was no effect of restraint on the numbers of cells recruited to express Fos protein in the dp part of the PVN [F(1,40) = 2.4; P = 0.1] (Fig. 5A), whereas both the mpd [F(1,40) = 1,550; P < 0.01] and mpv [F(1,40) = 493; P < 0.01] parts showed elevations in stress-induced Fos-ir (Fig. 5, A and C). For the mpv part of the PVN, there was a significant lesion x testosterone x restraint interaction [F(1,40) = 8.9; P < 0.01]. Sham, high-testosterone-replaced animals contributed to this interaction, showing the highest levels of Fos cell numbers under stress conditions (Fig. 5C). Significant effects of lesion [F(1,40) = 9.8; P < 0.01] and testosterone [F(1,40) = 16; P < 0.01] and a significant lesion x testosterone interaction [F(1,40) = 8.0; P < 0.01] were revealed in the mpd part of the PVN. Post hoc analysis confirmed that the inhibitory effect of testosterone on the number of Fos-ir cells in the mpd occurred in sham but not in MPN lesion animals (Fig. 5B).


Figure 4
View larger version (43K):
[in this window]
[in a new window]

 
Fig. 4. MPN lesions and testosterone interact on the induction of Fos expression in the medial parvocellular and dorsal part of the parvoventricular nucleus (PVN) provoked by acute restraint. Brightfield photomicrographs through a comparable level of the PVN in GDX, sham lesion rats bearing low- and high-testosterone replacement (B and C, respectively) at 60 min following the onset of 30 min of restraint exposure. The spatial pattern of Fos induction schematized (A) was cytoarchitectonically defined by redirected sampling of Nissl staining patterns aligned to adjacent corresponding brightfield images. Note, in high-testosterone animals (C), the relative decrement in Fos induction was contained within the region of the medial ventral parvocellular (mpv, see Fig. 5). Structures labeled for reference as follows: dp, dorsal parvocellular; mpd, medial dorsal parvocellular part; pm, posterior magnocellular part of the PVN. Scale bar = 150 µm (applies to A–C).

 

Figure 5
View larger version (17K):
[in this window]
[in a new window]

 
Fig. 5. Relative strength of Fos induction in the autonomic-related dp (A), mpv (C), and mpd (B) parvicellular subdivisions of the PVN. Mean ± SE no. of Fos-ir neurons at 60 min following the onset of 30 min of restraint exposure in GDX, low- and high-testosterone-replaced rats bearing sham- and IBO lesions in the MPN. *P < 0.05 vs. low-testosterone sham and MPN lesion animals; **P < 0.01 vs. low-testosterone sham and MPN lesion animals (n = 6/group).

 
Median eminence CRH- and AVP-ir. Our previous findings indicated that the inhibitory effect of testosterone on stress-induced ACTH release is associated with changes in AVP, but not CRH, content in the median eminence (50). Content measures of median eminence AVP provide, for the most part, an index of magnocellular activity, and both magnocellular and parvocellular neurosecretory neurons contribute to AVP in pituitary portal plasma (3). To provide a more precise index of parvocellular activity, in the current study, we used a dual immunohistochemical approach to detect CRH staining in the external zone of the median eminence and to assess the relative levels of AVP contained by these CRH terminals of medial parvocellular origin (Fig. 6). For CRH-ir, there were no main effects of lesion and testosterone. The lesion x testosterone interaction approached significance [F(1,20) = 3.8; P = 0.06], as reflected by a tendency for MPN lesion rats to show lower levels of CRH staining under high testosterone replacement (Fig. 7A). Analysis of AVP staining revealed significant effects of lesion [F(1,20) = 6.2; P < 0.05], testosterone [F(1,20) = 10.7; P < 0.01], and a significant lesion x testosterone interaction [F(1,20) = 10.4; P < 0.01]. As revealed by post hoc analysis, the lesion x testosterone interaction was based within the high testosterone replacement group, where AVP staining was significantly greater in sham than in MPN lesion animals (Fig. 7B). In low-testosterone rats, AVP staining was comparable between rats bearing sham and MPN lesions (P = 0.15).


Figure 6
View larger version (90K):
[in this window]
[in a new window]

 
Fig. 6. Anatomic and immunohistochemical characterization of corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP) staining in the median eminence of a control rat to illustrate a method for quantifying peptide staining intensity within nerve terminals directed at the anterior pituitary. Photomicrographs to show a dense accumulation of CRH-immunoreactive terminals in the external zone of the median eminence (B), with some accumulation also in the internal zone (29), whereas AVP staining is predominant within both the internal lamina and the external zone of the structure (A). A concurrent double-immunofluorescent detection method shows a strong superimposition of AVP staining within CRH terminals of the external zone (C). Assessment of the relative levels of AVP contained by these terminals of medial parvocellular origin was achieved by redirected sampling of the pattern of AVP juxtaposed to the profile of CRH staining in the external zone. The product of this sampling and subtraction procedure is shown in D. Structures labeled for reference as follows: zi, internal zone; ze, external zone. Scale bar = 75 µm (applies to all).

 

Figure 7
View larger version (11K):
[in this window]
[in a new window]

 
Fig. 7. MPN lesions and testosterone interact on medial parvocellular AVP terminal fibers in the median eminence under basal conditions. Mean ± SE terminal fiber staining densities of CRH (A) and AVP (B) under basal conditions within the external zone of the median eminence in GDX, low- and high-testosterone-replaced rats bearing sham and IBO lesions in the MPN. *P < 0.05 vs. sham low-testosterone-replaced counterpart (n = 6/group).

 
Amygdala CRH and AVP mRNA. Densitometric analyses of CRH mRNA through the extent of the central nucleus of the amygdala (CeA) under basal conditions (Fig. 8) indicated a significant effect of testosterone [F(1,20) = 4.6; P < 0.05] but revealed no significant effect of lesion and no significant lesion x testosterone interaction. The effect of testosterone was attributed to an overall inhibitory effect of high testosterone replacement on CRH expression in both sham and MPN lesion groups (Fig. 8D). Analysis of AVP mRNA in the anterodorsal part of the medial amygdala (Fig. 9) revealed significant effects of lesion [F(1,20) = 15.1; P < 0.01] and testosterone [F(1,20) = 62; P < 0.01] and a significant lesion x testosterone interaction [F(1,20) = 16.8; P < 0.01]. Post hoc analysis revealed that the AVP response to high testosterone replacement was significantly higher in shams compared with MPN lesion animals (Fig. 9D).


Figure 8
View larger version (75K):
[in this window]
[in a new window]

 
Fig. 8. Hybridization histochemical localization of CRH mRNA in the central nucleus of the amygdala (CeA). Representative darkfield photomicrographs of coronal sections through a comparable level of the CeA to show the relative strength of hybridization signal of sham animals that were GDX and replaced with low (A) or high (C) testosterone and of MPN lesion animals with high testosterone replacement (B). ot, Optic tract. Scale bar = 250 µm (applies to A–C). Mean ± SE relative levels of CeA mRNA to show a main effect of testosterone but no MPN x testosterone interaction (D). *P < 0.05 vs. low-testosterone-replaced counterpart (n = 6/group).

 

Figure 9
View larger version (69K):
[in this window]
[in a new window]

 
Fig. 9. Hybridization histochemical localization of AVP mRNA in the medial nucleus of the amygdala (MeA). Representative darkfield photomicrographs of coronal sections through a comparable level of the MeA to show the relative strength of hybridization signal of sham animals that were GDX and replaced with low (A) or high (C) testosterone and of MPN lesion animals with high testosterone replacement (B). Scale bar = 250 µm (applies to A–C). Mean ± SE relative levels of AVP mRNA to show a MPN x testosterone interaction (D). P < 0.05 vs. low testosterone replaced (*) and vs. high testosterone replaced counterpart (t) (n = 6/group).

 

    DISCUSSION
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Our previous experiments showed that lesioning a large extent of the medial preoptic area blocked the inhibitory effects of a single dose of testosterone replacement on HPA function (50). In the current study, we used four treatment groups, encompassing two background levels of testosterone replacement in GDX adult male rats bearing sham and MPN lesions specifically. Thus our current design allowed us to make new inroads on how central and peripheral components of the HPA axis responds to differences in circulating testosterone levels and whether the MPN is required for the dose-related effect of testosterone to occur.

The data implicate testosterone-sensitive pathways from the MPN in mediating both the activational response to stress and biosynthetic capacity of PVN neurosecretory neurons. Testosterone exerted a dose-related inhibitory effect on restraint-induced levels of Fos within the mpd part of the PVN as well as ACTH levels in plasma. Within the high testosterone replacement group, rats bearing MPN lesions showed higher levels of stress-induced Fos in the mpd PVN and plasma ACTH compared with shams. These findings suggest that testosterone inhibition of HPA effector neurons in the PVN is mediated by ARs located outside the nucleus and that the MPN is required for this mechanism to occur. The extent to which the lesions reflect the removal of testosterone actions that normally occur within or distal to the MPN cannot be ascertained at this point. However, microimplants of the AR antagonist hydroxyflutamide in the MPN can increase the ACTH response to restraint (57).

MPN-lesioned animals showed significantly higher levels of corticosterone both under basal and stress conditions than did sham-lesioned rats (Fig. 3B). However, we found no interaction between lesions and testosterone. This was obviously a consequence of the sham group of animals, showing only a slight testosterone-dependent decrement in corticosterone levels at 30 min of restraint exposure. This departure between ACTH and corticosterone disagrees with our previous experiments showing negative relations between testosterone and stress-induced ACTH and corticosterone in animals with testes (48, 50). Our previous GDX + testosterone experiments also show that stress-induced levels of ACTH and corticosterone vary strongly and negatively with testosterone (50), in animals replaced over the entire range of naturally occurring differences in plasma testosterone (~0.2–7 ng/ml). These findings could explain why we were unable to detect an inhibitory effect on corticosterone using a single, high dose of testosterone replacement. One may still argue that testosterone is of limited significance to the glucocorticoid response, at least in the current study. However, because of our restricted replacement regimen, we can only interpret our data in so far as determining the relative capacity of different central and peripheral components of the HPA axis to respond to a unique level of testosterone.

Our current design, nevertheless, exposed a potential autonomic involvement, perhaps at the level of the PVN, on how testosterone contributes to the net glucocorticoid response. In support of this possibility, sham animals bearing high testosterone replacement showed higher numbers of Fos-ir neurons in the mpv part of the PVN than low-testosterone-replaced animals under stress conditions (Fig. 5B). Because the mpv cells contribute to the long-descending influences of the PVN on the preganglionic spinal cord neurons controlling the adrenal response to ACTH (reviewed in Ref. 55), this increment in restraint-induced mpv Fos could account for the dissociation observed between ACTH and corticosterone release in sham animals with high testosterone. The mpv Fos response to high testosterone replacement was muted, however, in animals bearing MPN lesions, despite showing higher restraint-induced levels of corticosterone. This paradoxical finding is rescued, perhaps, when considering that the magnitude of the corticosterone response to stress occurs as a function of autonomic outflow in addition to ACTH release as executed by the recruitment of the mpd PVN motor neurons (5, 15). The connective properties of the cellular populations in the PVN that are differentially recruited as a function of testosterone and MPN lesions have not yet been defined. Thus the extent to which testosterone acts and interacts with the MPN on PVN mpv cells identified as projecting to the preganglionic spinal cord neurons requires further clarification. Nevertheless, it should be noted that the AR and the estrogen receptor-β isoform are uniquely distributed within autonomic-related cells of the PVN, including the dorsal, lateral, and ventral components of the medial parvocellular division (4). Thus the mpv PVN neurons appear as ideal candidates for mediating the actions of testosterone on autonomic function directly, whereas the influence of testosterone on hypophysiotropic function appears to be indirect. We propose that testosterone normally acts on both the autonomic and neuroendocrine arms of the PVN and that a balance between these systems defines the net glucocorticoid response to stress.

In response to high testosterone replacement, unstressed sham animals showed no change in CRH but a substantial increase in AVP staining localized to CRH-positive terminals in the external lamina of the median eminence (Figs. 6 and 7). AVP is a weak ACTH secretagogue but potently enhances the stimulatory effects of CRH on ACTH release (3). Thus the stimulatory effect of testosterone and the opposing influence of MPN lesions on AVP content in the median eminence under basal conditions would appear contradictory to effects observed on ACTH under stress conditions. It is generally conceived that resting state levels of CRH- and AVP-ir in the external zone of the median eminence reflect the capacity of the mpd neurons of the PVN to synthesize these peptides (3). As several previous studies have indicated, however, the relative release patterns and contributions of CRH and AVP to the ACTH response are stressor and context specific and cannot be inferred solely on the basis of basal measures of peptide content in the median eminence alone (2, 3). Our current findings indicate that testosterone requires a functioning MPN to inhibit the stress-induced activation of mpd neurons, as well as to redirect the capacity of these neurons to express AVP in favor of CRH. Taken together, this suggests that the inhibitory effect of testosterone on stress-induced ACTH does not occur as a consequence of the capacity of mpd neurons to express AVP but may be functionally coupled to the number of mpd neurons recruited to release peptide stores. The extent to which AVP release actually contributes to testosterone regulation of the HPA axis remains to be determined, and worthy of pursuit, since AVP is thought to be the key variable imparting situation-specific alterations in the magnitude of the ACTH response to stress (2, 3).

Our lesions targeted the caudal half of the MPN, which houses primarily {gamma}-aminobutyric acid (GABA)-ergic neurons in addition to the peptide galanin (6, 30). Although galanin has been implicated in the neuroendocrine regulation of reproduction and energy balance (22), its involvement in HPA regulation has not been approached. Although a dependence of cellular activation and peptide expression in the PVN on the integrity of MPN GABA inputs have yet to be established directly, several lines of evidence support this possibility. Testosterone induces GABA activity in the MPN (18, 59); and several GABA-rich projections to the PVN, including the MPN, are recruited to express Fos protein and glutamic acid decarboxylase mRNA during stress exposure (6, 34).

The MPN shows strong bidirectional connections with the medial amygdala (7, 39), and AVP expression in this region is extremely sensitive to changes in circulating testosterone levels (12). Several lines of evidence suggest an involvement of extrahypothalamic AVP neurons in mediating the central actions of testosterone on the HPA axis (17, reviewed in Ref. 55). Furthermore, the medial amygdala is critical for the HPA response to stressful stimuli, particularly emotional stressors, such as restraint (11, 16, 21, 28). Thus we wondered whether the MPN lesions could influence the AVP response to testosterone within this region of the amygdala (Fig. 9). As expected, sham animals displayed an increase in AVP mRNA levels in the medial nucleus of the amygdala in response to high testosterone replacement. This increment in AVP expression, however, was significantly reduced in animals bearing MPN lesions. Assessment of the relative levels of CRH mRNA in the CeA revealed no interactions between lesions and testosterone (Fig. 8), consistent with the fact that the MPN shows no direct projections to this region of the amygdala (39). Unlike the medial amygdala, the central nucleus (CeA) appears to be less important for HPA activation in response to restraint (11, 16, 32). Thus our findings argue against a role for the CeA in mediating the central actions of testosterone, at least in response to acute forms of psychological stressors. However, since we observed a main negative effect of testosterone on CRH expression in the CeA, variations in testosterone may differentially prepare the HPA response under more physical or systemic types of challenges (11, 32, 58).

Virtually all AVP cells in the medial amygdala of the rat are immunoreactive for ARs (12). Although this signifies a local mode of action, our current findings challenge the notion that testosterone regulates AVP neurons in the medial amygdala directly, subject to the influences of the MPN. The medial amygdala, like most limbic regions, has little or no projections to the hypophysiotropic zone of the PVN (8, 21, 31). The functional influences of the medial amygdala nuclei on the HPA axis, if at all mediated by AVP neurons, may instead involve potential relays in the BST and various hypothalamic structures, including the MPN (8, 21, 55). The extent to which any of these projections contain AVP, rely on testosterone, and depend on a functioning MPN remains worthy of pursuit. AVP pathways originating from the medial amygdala have been shown to contribute to a broad, but linked, array of behaviors associated with autonomic, emotional, and coping responses to stress (25). Taken together with our findings, the MPN stands out as an important neural substrate for harmonizing the central actions of testosterone on behavior and neuroendocrine stress responses.

Perspectives and Significance

It is interesting that the functional effects of MPN lesions were discriminated, for the most part, in high- but not in low-testosterone-replaced rats. Circulating levels of testosterone vary as a function of age, sexual experience, social status, time of day, and in response to stress (55). Insofar as the MPN is recruited to modulate neuroendocrine, autonomic, and behavioral responses to stress, this may very well depend, therefore, on gonadal status and situation-specific changes in testosterone secretion (17). It is important to note, at least in the current study, that, despite massive changes in central stress pathways and at the pituitary, a single dose of high testosterone did not have a large impact on the net corticosterone response. Previous studies have implicated a critical role for AVP in sustaining corticotroph responsiveness during chronic stress (2). Taken together, our findings may be relevant to understanding how testosterone determines normal adaptation under repeated stress conditions, in addition to affective disease states associated with changes in adrenal function and gonadal status. Indeed, genuine gender differences in depression and anxiety (33) and the association of depressive illness with hypogonadism in males (35, 36), suggest a potential role for testosterone in the predisposition of mood disorders related to HPA dysfunction. Taken together with the instability of testosterone levels in rodents and humans, and the strength to which the MPN and testosterone interact on the HPA axis, the MPN may be integral to individual differences in HPA function attributed to variations in testosterone release.

Our present findings underscore how testosterone can bridge several independent, yet converging influences on the PVN. The anatomic specificity by which the MPN influences the inhibitory effect of testosterone on HPA axis function still remains unsettled given the connectivity of the MPN with several other extended circuitries of the PVN, also rich in ARs (39, 56). This does not indict the utility of our present design, since it provides several tenable bases for revisiting how changes in endogenous testosterone levels are registered within the circuits described, and how this impacts the stress-induced activation of these projections to the PVN.


    GRANTS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
This study was supported by the Canadian Institutes of Health Research (V. Viau).


    ACKNOWLEDGMENTS
 
We thank Brenda Bingham, Megan Gray, and Jenny Wu for technical assistance.


    FOOTNOTES
 

Address for reprint requests and other correspondence: Victor Viau, Dept. of Cellular and Physiological Sciences, Life Sciences Centre, The Univ. of British Columbia, 2350 Health Sciences Mall, Vancouver, Canada BC V6T 1Z3 (e-mail: viau{at}interchange.ubc.ca)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


    REFERENCES
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Aguilera G. Regulation of pituitary ACTH secretion during chronic stress. Front Neuroendocrinol 15: 321–350, 1994.[CrossRef][Web of Science][Medline]
  2. Aguilera G, Rabadan-Diehl C. Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation. Regul Pept 96: 23–29, 2000.[CrossRef][Web of Science][Medline]
  3. Antoni FA. Vasopressinergic control of pituitary adrenocorticotropin secretion comes ofage. Front Neuroendocrinol 14: 76–122, 1993.[CrossRef][Web of Science][Medline]
  4. Bingham B, Williamson M, Viau V. Androgen and estrogen receptor-beta distribution within spinal-projecting and neurosecretory neurons in the paraventricular nucleus of the male rat. J Comp Neurol 499: 911–923, 2006.[CrossRef][Web of Science][Medline]
  5. Bornstein SR, Engeland WC, Ehrhart-Bornstein M, Herman JP. Dissociation of ACTH and glucocorticoids. Trends Endocrinol Metab 19: 175–180, 2008.[CrossRef][Web of Science][Medline]
  6. Bowers G, Cullinan WE, Herman JP. Region-specific regulation of glutamic acid decarboxylase (GAD) mRNA expression in central stress circuits. J Neurosci 18: 5938–5947, 1998.[Abstract/Free Full Text]
  7. Canteras NS, Simerly RB, Swanson LW. Organization of projections from the medial nucleus of the amygdala: a PHAL study in the rat. J Comp Neurol 360: 213–245, 1995.[CrossRef][Web of Science][Medline]
  8. Choi DC, Furay AR, Evanson NK, Ostrander MM, Ulrich-Lai YM, Herman JP. Bed nucleus of the stria terminalis subregions differentially regulate hypothalamic-pituitary-adrenal axis activity: implications for the integration of limbic inputs. J Neurosci 27: 2025–2034, 2007.[Abstract/Free Full Text]
  9. Choi DC, Furay AR, Evanson NK, Ulrich-Lai YM, Nguyen MM, Ostrander MM, Herman JP. The role of the posterior medial bed nucleus of the stria terminalis in modulating hypothalamic-pituitary-adrenocortical axis responsiveness to acute and chronic stress. Psychoneuroendocrinology 33: 659–669, 2008.[CrossRef][Web of Science][Medline]
  10. Dallman MF, Akana SF, Cascio CS, Darlington DN, Jacobson L, Levin N. Regulation of ACTH secretion: variations on a theme of B. Recent Prog Horm Res 43: 113–173, 1987.[Web of Science][Medline]
  11. Dayas CV, Buller KM, Day TA. Neuroendocrine responses to an emotional stressor: evidence for involvement of the medial but not the central amygdala. Eur J Neurosci 11: 2312–2322, 1999.[CrossRef][Web of Science][Medline]
  12. de Vries GJ, Panzica GC. Sexual differentiation of central vasopressin and vasotocinsystems in vertebrates: different mechanisms, similar endpoints. Neuroscience 138: 947–955, 2006.[CrossRef][Web of Science][Medline]
  13. Dong HW, Petrovich GD, Swanson LW. Topography of projections from amygdala to bed nuclei of the stria terminalis. Brain Res Brain Res Rev 38: 192–246, 2001.[CrossRef][Medline]
  14. Dong HW, Swanson LW. Projections from bed nuclei of the stria terminalis, posterior division: implications for cerebral hemisphere regulation of defensive and reproductive behaviors. J Comp Neurol 471: 396–433, 2004.[CrossRef][Web of Science][Medline]
  15. Engeland WC, Arnhold MM. Neural circuitry in the regulation of adrenal corticosterone rhythmicity. Endocrine 28: 325–332, 2005.[CrossRef][Web of Science][Medline]
  16. Feldman S, Conforti N, Itzik A, Weidenfeld J. Differential effect of amygdaloid lesions on CRF-41, ACTH and corticosterone responses following neural stimuli. Brain Res 658: 21–26, 1994.[Web of Science][Medline]
  17. Gomez F, Manalo S, Dallman MF. Androgen-sensitive changes in regulation of restraint-induced adrenocorticotropin secretion between early and late puberty in male rats. Endocrinology 145: 59–70, 2004.[Abstract/Free Full Text]
  18. Grattan DR, Selmanoff M. Castration-induced decrease in the activity of medial preoptic and tuberoinfundibular GABAergic neurons is prevented by testosterone. Neuroendocrinology 60: 141–149, 1994.[Web of Science][Medline]
  19. Guillery RW. On counting and counting errors. J Comp Neurol 447: 1–7, 2002.[CrossRef][Web of Science][Medline]
  20. Herbison A. Physiology of the gonadotropin-releasing hormone neuronal network. In: Knobil and Neill's Physiology of Reproduction (3rd ed.), edited by Neill J. San Diego, CA: Elsevier, 2006.
  21. Herman JP, Figueiredo H, Mueller NK, Ulrich-Lai Y, Ostrander MM, Choi DC, Cullinan WE. Central mechanisms of stress integration: hierarchical circuitry controlling hypothalamo-pituitary-adrenocortical responsiveness. Front Neuroendocrinol 24: 151–180, 2003.[CrossRef][Web of Science][Medline]
  22. Hohmann JG, Krasnow SM, Teklemichael DN, Clifton DK, Wynick D, Steiner RA. Neuroendocrine profiles in galanin-overexpressing and knockout mice. Neuroendocrinology 77: 354–366, 2003.[CrossRef][Web of Science][Medline]
  23. Kalra SP, Kalra PS. Neural regulation of luteinizing hormone secretion in the rat. Endocrine Rev 4: 311–351, 1983.[Abstract/Free Full Text]
  24. Lennard DE, Eckert WA, Merchenthaler I. Corticotropin-releasing hormone neurons in the paraventricular nucleus project to the external zone of the median eminence: a study combining retrograde labeling with immunocytochemistry. J Neuroendocrinol 5: 175–181, 1993.[CrossRef][Web of Science][Medline]
  25. Liebsch G, Wotjak CT, Landgraf R, Engelmann M. Septal vasopressin modulates anxiety-related behaviour in rats. Neurosci Lett 217: 101–104, 1996.[CrossRef][Web of Science][Medline]
  26. Lund TD, Hinds LR, Handa RJ. The androgen 5alpha-dihydrotestosterone and its metabolite 5alpha-androstan-3beta, 17beta-diol inhibit the hypothalamo-pituitary-adrenal response to stress by acting through estrogen receptor beta-expressing neurons in the hypothalamus. J Neurosci 26: 1448–1456, 2006.[Abstract/Free Full Text]
  27. Lund TD, Munson DJ, Haldy ME, Handa RJ. Androgen inhibits, while oestrogen enhances, restraint-induced activation of neuropeptide neurones in the paraventricular nucleus of the hypothalamus. J Neuroendocrinol 16: 272–278, 2004.[CrossRef][Web of Science][Medline]
  28. Ma S, Morilak DA. Norepinephrine release in medial amygdala facilitates activation of the hypothalamic-pituitary-adrenal axis in response to acute immobilisation stress. J Neuroendocrinol 17: 22–28, 2005.[CrossRef][Web of Science][Medline]
  29. Merchenthaler I, Vigh S, Petrusz P, Schally AV. Immunocytochemical localization of corticotropin-releasing factor (CRF) in the rat brain. Am J Anat 165: 385–396, 1982.[CrossRef][Web of Science][Medline]
  30. Polston EK, Simerly RB. Sex-specific patterns of galanin, cholecystokinin, and substance P expression in neurons of the principal bed nucleus of the stria terminalis are differentially reflected within three efferent preoptic pathways in the juvenile rat. J Comp Neurol 465: 551–559, 2003.[CrossRef][Web of Science][Medline]
  31. Prewitt CM, Herman JP. Anatomical interactions between the central amygdaloid nucleus and the hypothalamic paraventricular nucleus of the rat: a dual tract-tracing analysis. J Chem Neuroanat 15: 173–185, 1998.[CrossRef][Web of Science][Medline]
  32. Prewitt CM, Herman JP. Hypothalamo-pituitary-adrenocortical regulation following lesions of the central nucleus of the amygdala. Stress 1: 263–280, 1997.[Medline]
  33. Rubinow DR, Schmidt PJ. Gonadal steroids, brain and behavior: role of context. Dialogues Clin Neurosci 4: 123–137, 2002.
  34. Sarkar S, Zaretskaia MV, Zaretsky DV, Moreno M, DiMicco JA. Stress- and lipopolysaccharide-induced c-fos expression and nNOS in hypothalamic neurons projecting to medullary raphe in rats: a triple immunofluorescent labeling study. Eur J Neurosci 26: 2228–2238, 2007.[CrossRef][Web of Science][Medline]
  35. Schmidt PJ, Berlin KL, Danaceau MA, Neeren A, Haq NA, Roca CA, Rubinow DR. The effects of pharmacologically induced hypogonadism on mood in healthy men. Arch Gen Psychiatry 61: 997–1004, 2004.[Abstract/Free Full Text]
  36. Shores MM, Sloan KL, Matsumoto AM, Moceri VM, Felker B, Kivlahan DR. Increased incidence of diagnosed depressive illness in hypogonadal older men. Arch Gen Psychiatry 61: 162–167, 2004.[Abstract/Free Full Text]
  37. Silverman AJ, Jhamandas J, Renaud LP. Localization of luteinizing hormone-releasing hormone (LHRH) neurons that project to the median eminence. J Neurosci 7: 2312–2319, 1987.[Abstract]
  38. Simerly RB, Gorski RA, Swanson LW. Neurotransmitter specificity of cells and fibers in the medial preoptic nucleus: an immunohistochemical study in the rat. J Comp Neurol 246: 343–363, 1986.[CrossRef][Web of Science][Medline]
  39. Simerly RB, Swanson LW. Projections of the medial preoptic nucleus: a Phaseolus vulgaris leucoagglutinin anterograde tract-tracing study in the rat. J Comp Neurol 270: 209–242, 1988.[CrossRef][Web of Science][Medline]
  40. Simerly RB, Swanson LW. The organization of neural inputs to the medial preoptic nucleus of the rat. J Comp Neurol 246: 312–342, 1986.[CrossRef][Web of Science][Medline]
  41. Simmons DM, Arriza J, Swanson LW. A complete protocol for in situ hybridization of messenger RNAs in brain and other tissues with radiolabeled single-stranded RNA probes. J Histotechnol 12: 169–181, 1989.[Web of Science]
  42. Swanson LW. Brain Maps: Structure of the Rat Brain. San Diego, CA: Academic, 2004.
  43. Swanson LW, Kuypers HG. The paraventricular nucleus of the hypothalamus: cytoarchitectonic subdivisions and organization of projections to the pituitary, dorsal vagal complex, and spinal cord as demonstrated by retrograde fluorescence double-labeling methods. J Comp Neurol 194: 555–570, 1980.[CrossRef][Web of Science][Medline]
  44. Swanson LW, Sawchenko PE. Hypothalamic integration: organization of the paraventricular and supraoptic nuclei. Annu Rev Neurosci 6: 269–324, 1983.[CrossRef][Web of Science][Medline]
  45. Swanson LW, Simmons DM. Differential steroid hormone and neural influences on peptide mRNA levels in CRH cells of the paraventricular nucleus: a hybridization histochemical study in the rat. J Comp Neurol 285: 413–435, 1989.[CrossRef][Web of Science][Medline]
  46. Viau V, Bingham B, Davis J, Lee P, Wong M. Gender and puberty interact on the stress induced activation of parvocellular neurosecretory neurons and corticotropin-releasing hormone messenger ribonucleic acid expression in the rat. Endocrinology 146: 137–146, 2005.[Abstract/Free Full Text]
  47. Viau V, Chu A, Soriano L, Dallman MF. Independent and overlapping effects of corticosterone and testosterone on corticotropin-releasing hormone and arginine vasopressin mRNA expression in the paraventricular nucleus of the hypothalamus and stress-induced adrenocorticotropic hormone release. J Neurosci 19: 6684–6693, 1999.[Abstract/Free Full Text]
  48. Viau V, Lee P, Sampson J, Wu J. A testicular influence on restraint-induced activation of medial parvocellular neurons in the paraventricular nucleus in the male rat. Endocrinology 144: 3067–3075, 2003.[Abstract/Free Full Text]
  49. Viau V, Meaney MJ. Testosterone-dependent variations in plasma and intrapituitary corticosteroid binding globulin and stress hypothalamic-pituitary-adrenal activity in the male rat. J Endocrinol 181: 223–231, 2004.[Abstract]
  50. Viau V, Meaney MJ. The inhibitory effect of testosterone on hypothalamic-pituitary adrenal responses to stress is mediated by the medial preoptic area. J Neurosci 16: 1866–1876, 1996.[Abstract/Free Full Text]
  51. Viau V, Meaney MJ. Variations in the hypothalamic-pituitary-adrenal response to stress during the estrous cycle in the rat. Endocrinology 129: 2503–2511, 1991.[Abstract/Free Full Text]
  52. Viau V, Sawchenko PE. Hypophysiotropic neurons of the paraventricular nucleus respond in spatially, temporally, and phenotypically differentiated manners to acute vs. repeated restraint stress: rapid publication. J Comp Neurol 445: 293–307, 2002.[CrossRef][Web of Science][Medline]
  53. Viau V, Soriano L, Dallman MF. Androgens alter corticotropin releasing hormone and arginine vasopressin mRNA within forebrain sites known to regulate activity in the hypothalamic-pituitary-adrenal axis. J Neuroendocrinol 13: 442–452, 2001.[CrossRef][Web of Science][Medline]
  54. Watts AG. Glucocorticoid regulation of peptide genes in neuroendocrine CRH neurons: a complexity beyond negative feedback. Front Neuroendocrinol 26: 109–130, 2005.[CrossRef][Web of Science][Medline]
  55. Williamson M, Bingham B, Viau V. Central organization of androgen-sensitive pathways to the hypothalamic-pituitary-adrenal axis: implications for individual differences in responses to homeostatic threat and predisposition to disease. Prog Neuropsychopharmacol Biol Psychiatry 29: 1239–1248, 2005.[CrossRef][Medline]
  56. Williamson M, Viau V. Androgen receptor expressing neurons that project to the paraventricular nucleus of the hypothalamus in the male rat. J Comp Neurol 503: 717–740, 2007.[CrossRef][Web of Science][Medline]
  57. Williamson M, Viau V. Unmasking the functional influence of the medial preoptic nucleus on the hypothalamic-pituitary-adrenal axis using microimplants of hydroxyflutamide and testosterone (Abstract). Soc Neurosci Abstr 33: 732.2, 2007.
  58. Xu Y, Day TA, Buller KM. The central amygdala modulates hypothalamic-pituitary adrenal axis responses to systemic interleukin-1beta administration. Neuroscience 94: 175–183, 1999.[CrossRef][Web of Science][Medline]
  59. Yoo MJ, Searles RV, He JR, Shen WB, Grattan DR, Selmanoff M. Castration rapidly decreases hypothalamic gamma-aminobutyric acidergic neuronal activity in both male and female rats. Brain Res 878: 1–10, 2000.[CrossRef][Web of Science][Medline]
  60. Zimmerman EA, Stillman MA, Recht LD, Antunes JL, Carmel PW, Goldsmith PC. Vasopressin and corticotropin-releasing factor: an axonal pathway to portal capillaries in the zona externa of the median eminence containing vasopressin and its interaction with adrenal corticoids. Ann NY Acad Sci 297: 405–419, 1977.[CrossRef][Medline]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
295/4/R1020    most recent
90389.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Williamson, M.
Right arrow Articles by Viau, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Williamson, M.
Right arrow Articles by Viau, V.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.